iTeos Therapeutics Q1 2023 Earnings Report $6.99 -0.27 (-3.72%) As of 03/3/2025 04:00 PM Eastern Earnings HistoryForecast iTeos Therapeutics EPS ResultsActual EPS-$0.44Consensus EPS -$0.99Beat/MissBeat by +$0.55One Year Ago EPSN/AiTeos Therapeutics Revenue ResultsActual Revenue$12.60 millionExpected Revenue$13.80 millionBeat/MissMissed by -$1.20 millionYoY Revenue GrowthN/AiTeos Therapeutics Announcement DetailsQuarterQ1 2023Date5/10/2023TimeN/AConference Call ResourcesPress ReleaseITOS Earnings HistoryPowered by iTeos Therapeutics Earnings HeadlinesiTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success NeverthelessFebruary 27, 2025 | seekingalpha.comFinancial Review: iTeos Therapeutics (NASDAQ:ITOS) vs. enGene (NASDAQ:ENGN)February 27, 2025 | americanbankingnews.comThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR! He says these 5 stocks are trading for less than $2 right now… But they could soon SOAR in Trump’s first 100 days.March 4, 2025 | Timothy Sykes (Ad)Fate Therapeutics (NASDAQ:FATE) versus iTeos Therapeutics (NASDAQ:ITOS) Financial ContrastFebruary 22, 2025 | americanbankingnews.comITOS stock touches 52-week low at $7.09 amid market challengesFebruary 11, 2025 | msn.comWe Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth CarefullyFebruary 4, 2025 | finance.yahoo.comSee More iTeos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like iTeos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iTeos Therapeutics and other key companies, straight to your email. Email Address About iTeos TherapeuticsiTeos Therapeutics (NASDAQ:ITOS) is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.View iTeos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance? Upcoming Earnings Marvell Technology (3/5/2025)Broadcom (3/6/2025)Costco Wholesale (3/6/2025)JD.com (3/6/2025)Canadian Natural Resources (3/6/2025)Oracle (3/10/2025)Adobe (3/12/2025)PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
